Disease · MONDO_0019542
acute liver failure
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. acute liver failure. Diseases, record MONDO_0019542. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0019542
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs9
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| FRAMYCETIN | CHEMBL184618 | Small molecule | Approval | TTD | 1 | 0 | 0 | Drugs and targets |
| ACETYLCYSTEINE | CHEMBL600 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 3 | Drugs and targets |
| ORNITHINE | CHEMBL446143 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 1 | Drugs and targets |
| ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE) | CHEMBL2108981 | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets | |
| METHYLPREDNISOLONE | CHEMBL650 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| FILGRASTIM | CHEMBL1201567 | Protein | Unknown | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| LENOGRASTIM | CHEMBL2109128 | Protein | Unknown | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| ORNITHINE PHENYLACETATE | CHEMBL4297204 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PEGFILGRASTIM | CHEMBL1201568 | Protein | Unknown | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
Targets2
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| CSF3R | Granulocyte colony-stimulating factor receptor | 3 | Granulocyte colony stimulating factor receptor agonist | Unknown | https://conductscience.org/library/genes/1441 | Drugs and targets |
| NR3C1 | Glucocorticoid receptor | 1 | Glucocorticoid receptor agonist | Phase 2 | https://conductscience.org/library/genes/2908 | Drugs and targets |
Trials6
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 3 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00248625 | N-acetylcysteine in Non-Acetaminophen Pediatric Acute Liver Failure | Phase 3 | 184 | 2016-07-28 | Acute Liver Failure, Hepatic Encephalopathy | ACETYLCYSTEINE | Its record names the disease | ClinicalTrials.gov |
| NCT01548690 | Safety Study of Ornithine Phenylacetate to Treat Patients With Acute Liver Failure/Severe Acute Liver Injury | Phase 2 | 47 | 2018-09-20 | Acute Liver Failure, Acute Liver Injury | ORNITHINE | Its record names the disease | ClinicalTrials.gov |
| NCT00004467 | Randomized Study of Acetylcysteine in Patients With Acute Liver Failure Not Caused by Acetaminophen | Phase 3 | 173 | Acute Liver Failure | ACETYLCYSTEINE | Its record names the disease | ClinicalTrials.gov | |
| NCT04862221 | TReatment for ImmUne Mediated PathopHysiology | Phase 2 | 44 | Acute Liver Failure, Fulminant Hepatic Failure, Hepatic Encephalopathy, Acute Liver Injury, Immune Dysregulation | ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE), METHYLPREDNISOLONE | Its record names the disease | ClinicalTrials.gov | |
| NCT02718079 | High-Volume Plasma Exchange Versus Standard Medical Treatment in Patients With Acute Liver Failure | Not applicable | 40 | Acute Liver Failure | ACETYLCYSTEINE | Its record names the disease | ClinicalTrials.gov | |
| NCT01634230 | Emergency Use of OCR-002 in Acute Liver Failure (ALF) | Acute Liver Failure | ORNITHINE PHENYLACETATE | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials4
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| N-acetylcysteine (NAC) vs Placebo: Survival | 68 of 92 | 76 of 92 | 184 | NCT00248625 | Trial comparisons |
| N-acetylcysteine (NAC) vs Placebo: Infectious Complication | 20 of 92 | 21 of 92 | 184 | NCT00248625 | Trial comparisons |
| N-acetylcysteine (NAC) vs Placebo: Spontaneous Recovery | 33 of 92 | 49 of 92 | 184 | NCT00248625 | Trial comparisons |
| N-acetylcysteine (NAC) vs Placebo: serious adverse events | 5 of 92 | 4 of 92 | 184 | NCT00248625 | Trial comparisons |
Papers from its trials5
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0019542
GET https://conductscience.org/api/diseases/v1/MONDO_0019542/drugs